Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Prospective, Randomized, Multi-center, Open label, Phase 1/2 study to Evaluate the
Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2].
BSV has developed Equine COVID-19 antiserum from horse serum for the use in COVID-19
infection. The indication proposed is to provide passive immunization to the COVID-19
infected patient thereby reducing the viral load and prevention of disease progression.
Clinical phase 1 and phase 2 studies have been planned to be conducted. The phase 1 study
will be conducted on two dosages to find the safety and tolerability in patients. Based on
the results of phase 1 study the phase 2 shall be initiated.